Inovio Pharmaceuticals Teams with Akeso for Innovative Glioblastoma Treatment Development

Innovative Collaboration Targets Aggressive Brain Cancer Treatment

In a significant development for cancer therapy, INOVIO Pharmaceuticals has partnered with Akeso, Inc. to explore a new treatment for glioblastoma (GBM), an aggressive form of brain cancer known for its poor prognosis and limited treatment options. The collaboration focuses on evaluating INOVIO's INO-5412—an investigational drug that combines INO-5401 and INO-9012—alongside Akeso's cadonilimab, a novel PD-1/CTLA-4 bispecific antibody. This combination will be tested in a Phase 2 adaptive platform trial dubbed INSIGhT, which is sponsored by the Dana-Farber Cancer Institute and executed in collaboration with Mass General Brigham Cancer Care. Dosing for this important trial is projected to commence in the latter half of 2026, reflecting both companies' commitment to advancing therapeutic options for GBM patients.

The rationale behind this innovative combination lies in INO-5412's design to elicit an immune response by targeting tumor antigens, thereby increasing T cell infiltration within the tumor microenvironment. This mechanism aims to address the limitations often encountered with traditional immune checkpoint therapies when deployed independently. Previous Phase 2 trial results already show that the combination of INO-5401 and INO-9012, when used alongside a PD-1 inhibitor, may generate robust immune responses and correlate with improved survival rates in patients. By integrating cadonilimab, the collaboration seeks to deepen the therapeutic impact through dual checkpoint inhibition, possibly enhancing treatment efficacy.

This partnership exemplifies a growing trend in oncology where combination therapies are viewed as a viable solution to overcome the challenges posed by aggressive cancers like GBM. With conventional treatment avenues often falling short, both INOVIO and Akeso aim to pioneer a novel approach that harnesses the power of the immune system to combat this devastating disease. The INSIGhT trial not only embodies the hope for better patient outcomes but also represents a broader commitment within the biopharmaceutical industry to innovate and seek out transformative therapies for patients afflicted with hard-to-treat cancers.

In addition to this collaboration, it is worth noting that recent legal developments have emerged surrounding INOVIO Pharmaceuticals. Levi & Korsinsky, LLP has initiated a pending securities class action on behalf of investors who purchased INO stock between October 10, 2023, and December 26, 2025. This disclosure follows a guideline from the FDA regarding the review process for Inovio's Biologics License Application (BLA), which revealed that it would undergo standard review rather than accelerated approval, prompting significant stock price fluctuations.

As this ambitious project moves forward, the focus remains on developing innovative cancer solutions for patients battling GBM, underscoring the continuous effort within the biopharmaceutical sector to enhance treatment strategies through collaborative research and cutting-edge science.